The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of immune checkpoint inhibitors (ICI) in patients (pts) with pre-existing neurologic autoimmune diseases (NAID) and Parkinson's disease.
 
Kylie Fletcher
Stock and Other Ownership Interests - Immunovant (I)
 
Amin Nassar
No Relationships to Disclose
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; QBiotics; Roche
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Immunocore Ireland Limited; Innovent Biologics; IO Biotech; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Regeneron
 
Frank Aboubakar Nana
No Relationships to Disclose
 
Andrea Malgeri
Speakers' Bureau - Astellas Pharma
 
Alessio Cortellini
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; IQvia; MSD Oncology; OncoC4
Speakers' Bureau - AstraZeneca; Eisai
 
Shailee Shah
No Relationships to Disclose
 
Jessica Cecile Hassel
Honoraria - Amgen; BMS GmbH & Co. KG; Bristol Myers Squibb Foundation; GlaxoSmithKline; Immunocore; MSD; Novartis; Pierre Fabre; Sanofi; Sun Pharma
Consulting or Advisory Role - BMS GmbH & Co. KG (Inst); GlaxoSmithKline; Immunocore (Inst); MSD; Novartis (Inst); Onkowissen; Philogen (Inst); Pierre Fabre; Sanofi Aventis GmbH (Inst); Sun Pharma
Research Funding - 4SC (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Genmab (Inst); Idera (Inst); immatics (Inst); Immunocore (Inst); IO Biotech (Inst); Iovance Biotherapeutics (Inst); Nektar (Inst); Novartis (Inst); Philogen (Inst); Pierre Fabre (Inst); Regeneron (Inst); Replimune (Inst); Sanofi (Inst); Sanofi Aventis GmbH (Inst); Sun Pharma (Inst)
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Iovance Biotherapeutics; Sun Pharma
 
So Yeon Kim
Consulting or Advisory Role - Amgen
Research Funding - Boehringer Ingelheim (Inst); Genmab (Inst); Loxo/Lilly (Inst)
 
Abdul Rafeh Naqash
Honoraria - NGM Biopharmaceuticals
Consulting or Advisory Role - foundation me
Travel, Accommodations, Expenses - American Society for Radiation Oncology; ASCO; Binacea; Foundation Medicine; Jazz Pharmaceuticals (Inst); Society for Immunotherapy of Cancer
 
Pavan Challa
No Relationships to Disclose
 
Douglas Buckner Johnson
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck; Mosaic ImmunoEngineering; Novartis; Pfizer; Targovax
Research Funding - Bristol-Myers Squibb; Incyte
Patents, Royalties, Other Intellectual Property - Abatacept for the use of immune related adverse events.; Intellectual property and patents pending surrounding use of MHC-II and response to immune therapy